Replimune stock falls 3.79 percent as losses persist

Replimune Group stock (ISIN US76029N1063) fell 3.79 percent to USD 12.96 on Nasdaq on September 23, 2026, while its market capitalization stood at USD 1.09 billion. The biotech is balancing a narrower quarterly loss against a larger authorized share base.

Quarterly loss misses consensus

For fiscal Q1 2027, Replimune reported EPS of USD 0.72 negative, missing the USD 0.69 negative consensus estimate by USD 0.03, according to MarketBeat in its September 11, 2026 report.

The quarter ended June 30, 2026, and the net loss was USD 69.77 million, according to Simply Wall St. The loss remains the central earnings measure because the company has not yet established product revenue.

Share authorization reaches 300 million

Replimune stockholders approved an increase in authorized common shares from 150 million to 300 million, effective after a Delaware filing on September 15, 2026, according to the SEC. The change gives the company additional financing capacity, but it also creates potential dilution if new shares are issued.

The stock price remains USD 3.37 below its 52-week high of USD 16.33 and USD 11.46 above its 52-week low of USD 1.50. That spread shows why the September 23 decline matters less than the companys ability to convert its pipeline into commercial revenue.

Nasdaq price remains below high

Replimune was quoted at USD 12.96 on Nasdaq on September 23, 2026, with a daily change of negative 3.79 percent. Its 52-week range was USD 1.50 to USD 16.33, giving the stock a dated market reference for the next clinical and commercial milestones.